The primary pathways through which Icaritin exerts its anti-HCC effects include cancer pathways, PI3K-Akt signaling pathway, MAPK signaling pathway, resistance mechanisms to inhibitors of the epidermal growth factor receptor tyrosine kinase, and the HCC pathway. This evidence concerns the gene AKT1 and hepatocellular carcinoma.